Here’s What Makes Corcept Therapeutics (CORT) an Attractive Investment?
ClearBridge Investments, an investment management company, released its “Clearbridge Global Value Improvers Strategy” second-quarter 2025 investor letter.
Corcept Therapeutics Inc (CORT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 6,266,402 | $459,953,907 | +3% | 0.61% |
| 2. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 788,809 | $57,898,581 | -48% | 0.04% |
| 3. | D E Shaw D. E. Shaw | 673,137 | $49,408,256 | -4% | 0.04% |
| 4. | Driehaus Capital Richard Driehaus | 481,305 | $35,327,787 | +86% | 0.28% |
| 5. | Citadel Investment Group Ken Griffin | 446,004 | $32,736,693 | +1479% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.53 | 100,000 | $2,153,000.00 | 3,308,303 | 2021-06-11 | Filing | |
| $21.53 | 50,000 | $1,076,500.00 | 1,046,838 | 2021-06-11 | Filing | |
| $22.64 | 68 | $1,539.52 | 3,208,303 | 2020-12-01 | Filing | |
| $22.80 | 1,109 | $25,285.20 | 3,208,235 | 2020-11-30 | Filing | |
| $22.81 | 361 | $8,232.79 | 3,207,126 | 2020-11-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $87.54 | 2,200 | $192,588.00 | 0 | 2025-10-10 | Filing | |
| $89.94 | 20,000 | $1,798,782.00 | 5,287 | 2025-10-07 | Filing | |
| $85.67 | 3,194 | $273,617.84 | 2,781,370 | 2025-10-01 | Filing | |
| $85.16 | 31,190 | $2,656,265.16 | 2,784,564 | 2025-10-01 | Filing | |
| $84.29 | 5,616 | $473,369.83 | 2,815,754 | 2025-10-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 390,559 | $32,459,358 | 0.08% | |
| 2. | 29,277 | $2,433,211 | 0% | |
| 3. | 24,276 | $2,017,578 | 0.02% | |
| 4. | 14,340 | $1,191,797 | 0.07% | |
| 5. | 13,680 | $1,136,945 | 0.22% |
News See All
Corcept Therapeutics Beats Q2 Estimates, Cuts Guidance and Advances NDA for New Cancer Drug
Corcept Therapeutics Incorporated (NASDAQ:CORT) reported its Q2 2025 earnings on July 31, 2025, in which it highlighted a 45% EPS beat, achieving $0.29 per share against an estimated $0.20.
12 Stocks with Consistent Growth to Invest In
Volatility of the market often decides the nature of stocks preferred by an investor.
11 Best Performing Long Term Stocks According to Analysts
Alli McCartney of UBS noted that the market’s behavior after the recent Fed rate cut was unusual. On the day of the cut, major indices closed lower except for the Russell 2000.
Corcept's (CORT) Multibagger Momentum Builds on Relacorilant and Expanding Commercial Footprint
Corcept Therapeutics Inc. (NASDAQ:CORT) is one of the best multibagger stocks to invest in right now.
15 Best Multibagger Stocks to Invest in Right Now
Just as a single diamond can outshine a handful of pebbles, a well-chosen multibagger can transform an ordinary portfolio into an extraordinary one.
Canaccord Genuity Maintains a Buy on Corcept Therapeutics (CORT), Retains a $137 PT
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the most promising future stocks according to Wall Street analysts.
12 Most Promising Future Stocks According to Wall Street Analysts
Stockton further stated that while breadth hasn’t been great, it hasn’t been terrible either, not being wholly related to the mega caps.
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q2 2025 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to the Corcept Therapeutics Second Quarter 2025 Earnings Conference Call.
H.C. Wainwright Remains Bullish on Corcept Therapeutics Incorporated (CORT)
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the most profitable biotech stocks to invest in now. On July 14, H.C.